The agreement will enable health care providers to inject Fluorodeoxyglucose (FDG) for positron emission tomography/computed tomography (PET/CT) imaging procedures in a new way.
The partnership will leverage Medrad’s soon to be introduced Pet infusion system and multi-dose FDG packaging and delivery from Petnet Solutions. PET/CT Imaging is said to be effective in diagnosing and staging certain forms of cancer.
Petnet Solutions has agreed to provide FDG to customers throughout its extensive, cyclotron-based radiopharmacy network in multi-dose vials and specially designed vial shields, which will allow for easy integration with Medrad’s new system.
Alan Connor, director of global marketing for molecular imaging at Medrad, said: “We are very pleased that Petnet Solutions is the first FDG provider to agree to provide FDG in a manner compatible with the Intego System across its entire network.”